REG-Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
Key Highlights
- ➤Regeneron (REGN) receives $1 billion upfront from Sanofi
- ➤Regeneron (REGN) could receive up to $7 billion in milestone payments
- ➤Four long-acting antibodies added to Sanofi-Regeneron alliance
- ➤Companies will split development costs and future profits 50:50 globally
- ➤REGN20423 is in a Phase 1 atopic dermatitis study
Expert Statements
Belén Garijo, Chief Executive Officer of Sanofi
“This is a deliberate first step in igniting Sanofi’s innovation engine. Our longstanding Alliance with Regeneron has transformed the treatment landscape for millions of patients living with diseases driven by type 2 inflammation and created one of the world's leading immunology businesses.”
Belén Garijo, Chief Executive Officer of Sanofi
“By deepening our collaboration, we will make rapid progress in creating the next generation of meaningful therapies for patients with immune-mediated diseases, while contributing to Sanofi’s long-term future.”
Leonard S. Schleifer, Board co-Chair, President and Chief Executive Officer of Regeneron
“The Regeneron-Sanofi Alliance has been one of the most productive in biopharma history. This agreement builds on that foundation to bring the next generation of immunology medicines to patients even faster.”
Leonard S. Schleifer, Board co-Chair, President and Chief Executive Officer of Regeneron
“By expanding our Alliance, we are positioning promising new long-acting antibodies for the kind of rapid, global impact that our shared work on Dupixent has already achieved.”
George D. Yancopoulos, Board co-Chair, President and Chief Scientific Officer at Regeneron, and a principal inventor of Dupixent
“The companies’ clinical and commercial Alliance dates to 2003 and has resulted in multiple approved medicines to date, including Dupixent, which has redefined the standard of care for people with type 2 inflammatory diseases and is now one of the most widely used antibodies for any disease, with over 1.5 million active patients worldwide.”
George D. Yancopoulos, Board co-Chair, President and Chief Scientific Officer at Regeneron, and a principal inventor of Dupixent
“By combining Regeneron’s world-class scientific discovery and antibody development expertise with Sanofi’s global capabilities and reach, we hope to once again deliver the next wave of innovation in immunology.”
Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies * REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the Alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting pre-clinical antibodies from Regeneron * Regeneron to receive $1 billion upfront, with potential for up to an additional $7 billion in future milestone payments; companies to equally share development and commercialization costs, as well as any future profits * Sanofi and Regeneron to host a conference call for investors and analysts today at 14:00 CET/8:00am ET Paris and Tarrytown, NY, October 1, 2026. Sanofi and Regeneron Pharmaceuticals, Inc. today announce an expansion of their longstanding antibody collaboration, adding multiple next-generation, long-acting antibodies to the Alliance that has jointly established Dupixent® (dupilumab) as the world-leading treatment for diseases driven by type 2 inflammation. The agreement builds on the companies' more than 20-year collaboration, through which more than 1.5 million people are currently receiving Dupixent across nine indications, making it one of the most widely used antibody medicines in the world.
Get started
Create a free account to read the full story.